GlassScriptPhysician profile
Mara A Haseltine
NPI 1336317379
$276,093.60
in general payments reported to CMS, 2019-2025
41 companies · $113K in 2025
The $113K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,246 · 2020: $2,020 · 2021: $2,939 · 2022: $17K · 2023: $47K · 2024: $87K · 2025: $113K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $176K · Travel and Lodging: $25K · Food and Beverage: $18K · Consulting Fee: $14K · Honoraria: $13K · Education: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175,581.00 |
| Travel and Lodging | $24,863.74 |
| Food and Beverage | $18,493.06 |
| Consulting Fee | $14,243.50 |
| Honoraria | $12,600.00 |
| Education | $538.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $81,889.65 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $70,573.90 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $58,100.95 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Organon LLC | $14,680.99 | 2025 | Vtama |
| Kyowa Kirin, INC. | $12,874.67 | 2019-2025 | Poteligeo |
| Incyte Corporation | $8,264.41 | 2021-2025 | Opzelura |
| Genzyme Corporation | $5,655.35 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $4,848.91 | 2019-2025 | Valchlor |
| Janssen Biotech, INC. | $3,619.68 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $3,483.49 | 2019-2025 | |
| Lumenis Be INC | $2,011.57 | 2023 | M22 |
| Sun Pharmaceutical Industries INC. | $1,218.44 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $945.95 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $943.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $908.75 | 2019-2025 | Dupixent |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $863.53 | 2019-2024 | Jublia, Arazlo, Duobrii |
| Mayne Pharma Commercial LLC | $679.44 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $633.92 | 2023-2025 | Zoryve |
| Pfizer INC. | $624.41 | 2019-2025 | |
| Allergan, INC. | $549.79 | 2019-2022 | |
| Lilly USA, LLC | $429.19 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $421.58 | 2019-2025 | Otezla, Otezla |
| Biofrontera INC. | $370.88 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $323.08 | 2019-2025 | Seysara, Klisyri |
| Leo Pharma INC. | $239.28 | 2019-2025 | Adbry, Anzupgo |
| Journey Medical Corporation | $173.63 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $150.20 | 2020-2021 | |
| Botanix Sb INC | $136.93 | 2025 | Sofdra |
| Epi Health, LLC | $120.75 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Merz North America, INC. | $44.13 | 2019-2020 | |
| Medimetriks Pharmaceuticals, INC. | $35.33 | 2024-2025 | Clindacin Etz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.37 | 2024 | Cyltezo |
| Verrica Pharmaceuticals INC. | $26.07 | 2023 | Ycanth |
| Genentech USA, INC. | $22.16 | 2022 | |
| Dermira, INC. | $19.58 | 2020 | |
| Aclaris Therapeutics, INC. | $19.31 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.13 | 2019 | |
| Mission Pharmacal Company | $16.07 | 2021 | |
| Ani Pharmaceuticals, INC. | $13.61 | 2023 | Apexicon E |
| Prugen, INC. Pharmaceuticals | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Haseltine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.